Wells Fargo Maintains Overweight on Ascendis Pharma, Raises Price Target to $262
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila has maintained an Overweight rating on Ascendis Pharma (NASDAQ:ASND) and increased the price target from $260 to $262.
May 03, 2024 | 6:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo maintains an Overweight rating on Ascendis Pharma and raises the price target from $260 to $262.
The increase in price target by a reputable analyst like Derek Archila suggests a positive outlook on Ascendis Pharma's stock, potentially leading to increased investor confidence and a short-term price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100